Lupin is reportedly considering a demerger of its active pharmaceutical ingredients (API) business, following in the footsteps of Glenmark Pharma. The specifics of the demerger, such as a potential listing or stake sale, are yet to be determined.
Private Capital in India healthcare has registered yet another strong year in 2022. Despite a muted macroeconomic environment, the Indian Healthcare sector’s US$5.7Bn+ private capital ..
Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company, today announced its financial results for the fourth quarter en